title: Post-initiation effects of a super critical extract of propolis in a rat two-stage carcinogenesis model in female F344 rats.
abstract: Post-initiation modifying effects of dietary administration of a super critical extract of propolis on major organs were examined using a two-stage carcinogenesis model. Groups of 21 or 22 F344 female rats were treated sequentially with 2,2'-dihydroxy-di-n-propylnitrosamine (DHPN, i.g.), 7,12-dimethylbenz[a]anthracene (DMBA, i.g.), 1,2-dimethylhydrazine (DMH, s.c.) and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN, in drinking water) during the first 3 weeks for initiation, and then administered diet containing 0.1 or 0.01% propolis for 33 weeks. Further groups were treated with the carcinogens alone, 0.1% propolis alone or basal diet alone. All surviving animals were killed at week 36, and major organs were examined histopathologically for development of preneoplastic and neoplastic lesions. The incidence and multiplicity of mammary carcinomas were significantly decreased by the 0.1 and 0.01% propolis treatments. In the urinary bladder, the incidence of PN hyperplasia but not tumors was, in contrast, significantly increased by 0.1% propolis. Similarly, the number and area of glutathione S-transferase placental form (GST-P)-positive liver foci were significantly elevated with this high dose. The results indicate that a low dose of a super critical extract of propolis may find application as a potent chemopreventor of mammary carcinogenesis.
authors.affiliation: First Department of Pathology, Nagoya City University Medical School, Nagoya, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kimoto
authors.forename: M
authors.initials: M
authors.lastname: Hirose
authors.forename: M
authors.initials: M
authors.lastname: Kawabe
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: H
authors.initials: H
authors.lastname: Miyataka
authors.forename: T
authors.initials: T
authors.lastname: Shirai
mesh_terms: D019813:1,2-Dimethylhydrazine; D015127:9,10-Dimethyl-1,2-benzanthracene; D000284:Administration, Oral; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002085:Butylhydroxybutylnitrosamine; D015197:Carcinogenicity Tests; D002273:Carcinogens; D018890:Chemoprevention; D003106:Colon / Q000187:drug effects / Q000473:pathology; D005260:Female; D005982:Glutathione Transferase / Q000378:metabolism; D006965:Hyperplasia / Q000139:chemically induced / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D009602:Nitrosamines; D009929:Organ Size / Q000187:drug effects; D011429:Propolis / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D009602:Nitrosamines; D002085:Butylhydroxybutylnitrosamine; C012457:diisopropanolnitrosamine; D015127:9,10-Dimethyl-1,2-benzanthracene; D011429:Propolis; D005982:Glutathione Transferase; D019813:1,2-Dimethylhydrazine